Risankizumab trumps ustekinumab, placebo for moderate-to-severe psoriasis
10 Dec 2020
byAudrey Abella
The novel, humanized IgG1 monoclonal antibody risankizumab was superior to ustekinumab and placebo in reducing and potentially eliminating symptoms of moderate-to-severe chronic plaque psoriasis, according to two replicate phase III trials.
Risankizumab trumps ustekinumab, placebo for moderate-to-severe psoriasis
10 Dec 2020
